SCHEMBL26346751

SCHEMBL26346751

COc1cc2nn([C@H]3CC[C@H](C(C)C)CC3)cc2cc1NC(=O)c1ccccn1

nearest known ligand 0.62

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 20/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26346864 0.90 IRAK4 (0.58) IRAK4
SCHEMBL26355131 0.90 IRAK4 (0.63) IRAK4
SCHEMBL22848515 0.90 IRAK4 (0.59) IRAK4
SCHEMBL26355616 0.90 IRAK4 (0.59) IRAK4
SCHEMBL22849157 0.89 IRAK4 (0.59) IRAK4
SCHEMBL22848719 0.89 IRAK4 (0.64) IRAK4
SCHEMBL22848897 0.89 IRAK4 (0.63) IRAK4
SCHEMBL22835275 0.88 IRAK4 (0.61) IRAK4
SCHEMBL22835280 0.88 IRAK4 (0.61) IRAK4
SCHEMBL29502346 0.88 IRAK4 (0.61) IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 IRAK4 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.